Mizuho Securities analyst Steven Valiquette maintained a Buy rating on Veeva Systems (VEEV – Research Report) yesterday and set a price target of $280.00.
Steven Valiquette has given his Buy rating due to a combination of factors that highlight Veeva Systems’ strong financial performance and strategic positioning. The company’s guidance for fiscal year 2026 exceeded market expectations, with projected earnings per share and revenue surpassing analysts’ estimates. This positive outlook is supported by Veeva’s recent expansion with a major top 20 customer, which is adopting Veeva’s R&D platform extensively, indicating potential for further growth in their R&D solutions.
Furthermore, Veeva’s Commercial Cloud segment demonstrated solid revenue growth, and despite competitive pressures, the company maintains a competitive edge with its AI capabilities integrated into its CRM offerings. Veeva’s strategy of including AI solutions within existing products without additional charges is seen as a value addition for its biopharma customer base. Although there are some industry challenges, such as CRO pressure and NIH funding risks, Valiquette’s confidence in Veeva’s margin improvements and strategic initiatives supports the Buy rating.
In another report released yesterday, Citi also reiterated a Buy rating on the stock with a $307.00 price target.
VEEV’s price has also changed slightly for the past six months – from $215.890 to $236.140, which is a 9.38% increase.